Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice

  • Authors:
    • Zongqing Tan
    • Pingping Chen
    • Nathan Schneider
    • Samuel Glover
    • Lingling Cui
    • Julien Torgue
    • Olivier Rixe
    • Henry B. Spitz
    • Zhongyun Dong
  • View Affiliations

  • Published online on: February 6, 2012     https://doi.org/10.3892/ijo.2012.1357
  • Pages: 1881-1888
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to determine therapeutic effects and systemic toxicity of 212Pb-trastuzumab in an orthotopic model of human prostate cancer cells in nude mice. TCMC-Trastuzumab was radiolabeled with 212Pb. The 212Pb-trastuzumab generated from the procedure was intact and had high binding affinity with a dissociation constant (of 3.9±0.99 nM. PC-3MM2 cells, which expressed a lower level of HER2 both in culture and in tumors, were used in therapy studies. A single intravenous injection of 212Pb-trastuzumab reduced tumor growth by 60-80%, reduced aortic lymph node metastasis, and prolonged the survival of tumor-bearing mice. Treatment with 212Pb-trastuzumab did not cause significant changes in body weight, serum glutamic pyruvic transaminase (SGPT), blood urea nitrogen (BUN), hematological profiles, and histological morphology of several major organs of tumor-bearing mice. These findings suggest that a systemic delivery of 212Pb-trastuzumab could be an effective modality for management of advanced human prostate cancer.

Related Articles

Journal Cover

June 2012
Volume 40 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, Rixe O, Spitz HB and Dong Z: Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol 40: 1881-1888, 2012
APA
Tan, Z., Chen, P., Schneider, N., Glover, S., Cui, L., Torgue, J. ... Dong, Z. (2012). Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. International Journal of Oncology, 40, 1881-1888. https://doi.org/10.3892/ijo.2012.1357
MLA
Tan, Z., Chen, P., Schneider, N., Glover, S., Cui, L., Torgue, J., Rixe, O., Spitz, H. B., Dong, Z."Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice". International Journal of Oncology 40.6 (2012): 1881-1888.
Chicago
Tan, Z., Chen, P., Schneider, N., Glover, S., Cui, L., Torgue, J., Rixe, O., Spitz, H. B., Dong, Z."Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice". International Journal of Oncology 40, no. 6 (2012): 1881-1888. https://doi.org/10.3892/ijo.2012.1357